Stock ACE ASCELIA PHARMA AB
Add to a list
To use this feature you must be a member
Log inSign up

Financials Ascelia Pharma AB

Equities

ACE

SE0010573113

Biotechnology & Medical Research

Market Closed - Nasdaq Stockholm
Other stock markets
 11:29:50 2024-04-26 am EDT 		5-day change 1st Jan Change
11.16 SEK +5.28% Intraday chart for Ascelia Pharma AB -15.33% +231.16%
Apr. 10 Ascelia Pharma Reports SPARKLE Image Reading Completion and Expects Headline Results First Half of May 2024 CI
Feb. 09 Ascelia Pharma AB Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023 CI

Valuation

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Capitalization 1 554.3 1,590 1,005 503 113.8 376.7 - -
Enterprise Value (EV) 1 329.3 1,407 743.4 353.4 91.91 358.4 319.7 496.7
P/E ratio - -15 x -7.81 x -3.96 x - -8.68 x -4.51 x -4.65 x
Yield - - - - - - - -
Capitalization / Revenue - - - - - - - 11.6 x
EV / Revenue - - - - - - - 15.3 x
EV / EBITDA - -15.1 x -5.39 x -2.4 x -0.83 x -7.71 x -3.3 x -5.71 x
EV / FCF - -16.4 x -6.38 x -2.82 x -0.72 x -8.64 x -3.4 x -9.74 x
FCF Yield - -6.11% -15.7% -35.4% -138% -11.6% -29.4% -10.3%
Price to Book - 6.28 x 3.35 x 2.88 x - 10.3 x 1.64 x 3.72 x
Nbr of stocks (in thousands) 23,489 28,187 33,668 33,668 33,758 33,758 - -
Reference price 2 23.60 56.40 29.85 14.94 3.370 11.16 11.16 11.16
Announcement Date 8/22/19 2/16/21 2/10/22 2/10/23 2/9/24 - - -
1SEK in Million2SEK
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net sales 1 - - - - - - - 32.5
EBITDA 1 - -93.43 -137.9 -147 -110.9 -46.5 -97 -87
EBIT 1 -37.39 -93.43 -137.9 -147 -110.9 -46.5 -97 -87.5
Operating Margin - - - - - - - -269.23%
Earnings before Tax (EBT) 1 - -99.75 -129.5 -133.2 - -37 -102 -
Net income 1 - -98.7 -125.9 -131.2 - -37 -102 -
Net margin - - - - - - - -
EPS 2 - -3.760 -3.820 -3.770 - -1.285 -2.475 -2.400
Free Cash Flow 1 - -85.92 -116.6 -125.3 -126.8 -41.5 -94 -51
FCF margin - - - - - - - -156.92%
FCF Conversion (EBITDA) - - - - - - - -
FCF Conversion (Net income) - - - - - - - -
Dividend per Share - - - - - - - -
Announcement Date 8/22/19 2/16/21 2/10/22 2/10/23 2/9/24 - - -
1SEK in Million2SEK
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: December 2021 Q3 2021 Q4 2022 Q1 2022 Q2 2022 Q3 2022 Q4 2023 Q2 2023 Q3 2023 Q4 2024 Q1 2024 Q2 2024 Q3 2024 Q4
Net sales 1 - - - - - - - - - - - - -
EBITDA 1 - - - - - -52.17 - - - -14 -14 -14 -16
EBIT 1 -32.74 -39.16 -32.57 -32.65 -29.62 -52.17 - -21.36 - -14 -14 -14 -16
Operating Margin - - - - - - - - - - - - -
Earnings before Tax (EBT) -29.82 -36.13 -30.03 -23.8 -26.09 -53.24 - - - - - - -
Net income -28.52 -35.07 -29.08 -22.81 -25.96 -53.38 -40.25 - - - - - -
Net margin - - - - - - - - - - - - -
EPS - - - - - -1.530 -1.190 -0.6300 - - - - -
Dividend per Share - - - - - - - - - - - - -
Announcement Date 11/4/22 2/10/22 5/11/22 8/18/22 11/4/22 2/10/23 8/18/23 11/8/23 2/9/24 - - - -
1SEK in Million
Estimates

Balance Sheet Analysis

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net Debt 1 - - - - - - - 120
Net Cash position 1 225 183 262 150 21.9 18.4 57 -
Leverage (Debt/EBITDA) - - - - - - - -1.379 x
Free Cash Flow 1 - -85.9 -117 -125 -127 -41.5 -94 -51
ROE (net income / shareholders' equity) - -41.7% -46.3% -53.7% -85.7% -75% -383% 105%
ROA (Net income/ Total Assets) - - - - - - - -
Assets 1 - - - - - - - -
Book Value Per Share 2 - 8.990 8.900 5.190 - 1.080 6.800 3.000
Cash Flow per Share - -3.260 -3.540 -3.600 - - - -
Capex 1 - - - - - - - -
Capex / Sales - - - - - - - -
Announcement Date 8/22/19 2/16/21 2/10/22 2/10/23 2/9/24 - - -
1SEK in Million2SEK
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

1st Jan change Capi.
ASCELIA PHARMA AB Stock Ascelia Pharma AB
+231.16% 34.36M
IQVIA HOLDINGS INC. Stock Iqvia Holdings Inc.
+1.51% 42.75B
LONZA GROUP AG Stock Lonza Group AG
+49.22% 41.61B
MODERNA, INC. Stock Moderna, Inc.
+8.57% 41.34B
CELLTRION, INC. Stock Celltrion, Inc.
-12.36% 26.59B
ICON PUBLIC LIMITED COMPANY Stock ICON Public Limited Company
+8.92% 25.49B
ALNYLAM PHARMACEUTICALS, INC. Stock Alnylam Pharmaceuticals, Inc.
-25.13% 18.12B
MEDPACE HOLDINGS, INC. Stock Medpace Holdings, Inc.
+29.17% 12.24B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. Stock Charles River Laboratories International, Inc.
-3.12% 11.76B
UNITED THERAPEUTICS CORPORATION Stock United Therapeutics Corporation
+6.35% 11B
Other Biotechnology & Medical Research
  1. Stock Market
  2. Equities
  3. ACE Stock
  4. Financials Ascelia Pharma AB